|1.||Colao, Annamaria: 21 articles (03/2012 - 06/2002)|
|2.||Jenner, Peter: 20 articles (11/2015 - 02/2002)|
|3.||Lang, Anthony E: 19 articles (08/2015 - 01/2002)|
|4.||Antonini, Angelo: 18 articles (02/2015 - 05/2006)|
|5.||Bonuccelli, Ubaldo: 17 articles (11/2014 - 01/2002)|
|6.||Trenkwalder, Claudia: 14 articles (04/2014 - 01/2004)|
|7.||Molitch, Mark E: 13 articles (05/2015 - 10/2002)|
|8.||Rascol, Olivier: 13 articles (03/2014 - 07/2003)|
|9.||Ferini-Strambi, Luigi: 12 articles (03/2015 - 11/2003)|
|10.||Lees, Andrew J: 12 articles (01/2014 - 09/2002)|
|1.||Parkinson Disease (Parkinson's Disease)
01/01/2008 - "Considerable methodological differences in the identified studies complicate a comparison and impede clear evidence as to which dopamine agonist treatment is the most cost effective in early Parkinson's disease. "
10/01/2007 - "At present, dopamine agonists play an important role in antiparkinsonian therapy since they were proved effective in the management of both advanced- and early-stage Parkinson's disease. "
04/01/1995 - "These findings suggest that combination therapy with a partial D2 agonist and a full D1 agonist or monotherapy with a dopamine agonist that has both partial D2 and full D1 agonist properties might be beneficial for treating motor dysfunction in Parkinson's disease without inducing dopaminergic side effects."
12/01/2003 - "Oral dopamine agonists are effective for treating early Parkinson's disease (PD). "
12/01/2003 - "Dopamine agonists are effective in the management of both advanced and early-stage Parkinson's disease. "
11/01/2013 - "Most commonly occurs as microprolactinoma (less than 1cm in size), which may be cured with medical therapy, but few long-term studies are available about optimal duration of treatment with dopamine agonists to ensure cure after drug discontinuation and its withdrawal without recurrence are do not report consistent results. "
05/25/2001 - "In the case of a prolactinoma medical treatment with dopamine receptor agonists is the therapy of choice because it causes rapid tumour shrinkage and symptomatic improvement in most patients, so that irradition of the tumour is not indicated. "
08/01/2011 - "Complete remission of macroprolactinoma after long-term medical therapy with dopamine agonists."
01/01/2007 - "Remission rate was very high (90%) among women with microprolactinoma not treated with dopamine agonist before the surgical treatment. "
12/01/2012 - "The rapid improvement achieved negated the requirement for surgery and this highlights the efficacy of the dopamine agonists in the management of giant prolactinomas, even in the presence of neurological symptoms."
05/01/2005 - "Dopamine agonists are effective in the management of PRL-secreting tumors; they cause marked reversible tumor shrinkage in the substantial majority of patients. "
08/01/2006 - "Remission was significantly associated with being off of a dopamine agonist at the time of GKRS and a tumor volume less than 3.0 cm3 (P < 0.05 for both). "
11/01/1999 - "The majority, of PRL-secreting tumors can be effectively treated with dopamine agonists. "
10/01/2015 - "Surgical resection can also be considered as a primary treatment for those with smaller focal tumors where a biochemical cure can be expected as an alternative to lifelong dopamine agonist treatment. "
06/01/2015 - "All dopamine agonist-resistant tumors and all grade 2b (invasive and proliferative) tumors (from ten men and four women) were characterized by low ERα expression. "
|4.||Restless Legs Syndrome (Restless Legs)
07/19/2011 - "Review: Dopamine agonists are effective for the restless legs syndrome but may be discontinued due to adverse events."
08/01/2011 - "Safety and efficacy of non-ergot dopamine agonists for the treatment of idiopathic restless legs syndrome have been shown in short-term trials. "
09/01/2004 - "Controlled clinical trials robustly demonstrate the short-term efficacy of dopamine agonists (DA) for restless legs syndrome (RLS), but little is known about the long-term efficacy and long-term adverse events. "
01/01/2013 - "In the last few years, dopamine agonists (DA) have been used as first-line treatment for restless legs syndrome (RLS), a disabling sensorimotor disorder. "
01/01/2011 - "According to clinical guidelines, dopamine agonists are the first-line treatment of restless legs syndrome (RLS). "
01/01/1985 - "The concept of "transient hyperprolactinemia' is analyzed and alternative explanations for the positive results of dopamine agonist therapy in this particular condition are proposed. "
01/01/2014 - "A cross-sectional echocardiographic study was performed in a large group of patients who were receiving dopamine agonist therapy for hyperprolactinemia. "
07/01/2013 - "Our data support recent evidence that the serum PRL concentration is rarely >1000 mIU/l in males, or >2000 mIU/l in females, with non-functioning macroadenomas and that, once other contributing factors to the hyperprolactinemia have been excluded, a trial of dopamine agonist therapy for such lesions is indicated."
02/01/2012 - "This study investigated the differences in clinical and laboratory features as well as treatment response in 70 outpatients with macroprolactinemia and monomeric hyperprolactinemia treated with dopamine agonists. "
07/01/2003 - "A further study on non-operated Ménière's patients presenting hyperprolactinemia and on dopamine agonist treatment, is needed in order to assess the role of stress in Ménière's patients. "
|1.||Levodopa (L Dopa)
|5.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|9.||amsonic acid (DAS)
|2.||Activities of Daily Living (ADL)
|3.||Self Administration (Administration, Self)